BeyondSpring announced that it hosted a virtual Research and Development, R&D, Day to discuss its lead asset Plinabulin, a dendritic cell, DC, maturation agent, in drug combinations to potentially address the current unmet medical needs in cancer indications where patients failed prior PD-1/PD-L1 inhibitors, as well as updates for SEED Therapeutics which focuses on target protein degradation, TPD, platform for innovative molecular glue drug discovery on May 15, 2024. “Additionally, significant headway is being made through various Investigator-Initiated Trial (IIT) studies of plinabulin at leading institutions in the U.S. and China. Preliminary results are expected to be reported in 2H 2024, that are expected to reinforce our unique MOA and lead to a transformative year for BeyondSpring. If interim clinical data from our ongoing studies further validates our unique MOA, then we will look for opportunities to extend and accelerate plinabulin’s outreach through third-party partnerships,” said Dr. Lan Huang, Co-Founder, Chairman and CEO of BeyondSpring.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BYSI:
- BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
- BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
- BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
- BeyondSpring Files 2023 Annual Report on Form 20-F
- BeyondSpring reports first patient dosed with pembrolizumab, plinabulin plus EP